

Neuropsychopharmacology

A 281

www.elsevier.com/locate/euroneuro

Functional remediation for patients with bipolar II disorder: Improvement of functioning and subsyndromal symptoms **



Brisa Solé^a, C. Mar Bonnin^a, María Mayoral^b, Benedikt L. Amann^c, Imma Torres^a, Ana González-Pinto^d, Esther Jimenez^a, Jose Manuel Crespo^e, Francesc Colom^a, Rafael Tabarés-Seisdedos^f, Maria Reinares^a, Jose Luis Ayuso-Mateos^g, Sara Soria^h, M. Paz Garcia-Portillaⁱ, Ángela Ibañez^j, Eduard Vieta^{a,*}, Anabel Martinez-Aran^{a,*}, Carla Torrent^a, the CIBERSAM Functional Remediation Group¹

Received 13 March 2014; accepted 3 May 2014

^aBarcelona Bipolar Disorders Program, Institute of Neurosciences, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain

^bGregorio Marañón University General Hospital and Health Research Institute (IISGM), CIBERSAM, Madrid, Spain ^cFIDMAG Research Foundation Germanes Hospitalàries, CIBERSAM, Barcelona, Spain

dÁlava University Hospital, CIBERSAM, University of the Basque Country, Kronikgune, Vitoria, Spain

^eDepartment of Psychiatry, University Hospital of Bellvitge, Bellvitge Biomedical Research Institute (IDIBELL), CIBERSAM, Barcelona, Spain

[†]Department of Medicine, University of Valencia, CIBERSAM, Valencia, Spain

⁹Department of Psychiatry, Autonomous University of Madrid, Research Institute of the Hospital de la Princesa, CIBERSAM, Madrid, Spain

^hDepartment Clinical Psychology, Hospital Universitari Clínic; Universitat de Barcelona, Spain [†]Department of Psychiatry, University of Oviedo, CIBERSAM, Spain

¹Department of Psychiatry, Ramon y Cajal Hospital, Alcalá University, IRYCIS, CIBERSAM, Madrid, Spain

^{*}Clinicaltrials.gov identification number: NCT 01370668.

^{*}Correspondence to: Bipolar Disorder Program. Clinical Institute of Neuroscience. Hospital Clinic of Barcelona, Villarroel, 170. 08036 Barcelona, Spain. Tel.: +34 93 227 54 01; fax: +34 93 227 9228.

E-mail addresses: evieta@clinic.ub.es (E. Vieta), amartiar@clinic.ub.es (A. Martinez-Aran).

¹The CIBERSAM Functional Remediation Group consists of: Analucía Alegría, Susana Al-Halabi, Silvia Alonso-Lana, Celia Anaya, Celso Arango, Vicent Balanzá-Martínez, Sara Barbeito, Julio Bobes, Guadalupe Chiclana, Esther Cerrillo, Patricia Correa, Núria Custal, Patricia Fernández, Miryam Fernández, Inmaculada Fuentes-Durá, Gonzalo Galván, Sandra Isella, Ramon Landín-Romero, José Manuel Menchón, Jessica Merchan-Naranjo, Jordi Ortiz-Gil, Isabella Pacchiarotti, Raquel Reyes, Adriane R Rosa, Marta Rapado, José Maria Rodao, Pilar A Saiz, Jose Sánchez-Moreno, Bárbara Segura, Gabriel Selva-Vera, Jerónimo Saiz-Ruiz, Virginia Soria, Marta Subirá, Amaia Ugarte, Jesús Valle, Patricia Vega.

258 B. Solé et al.

KEYWORDS

Bipolar II disorder; Cognitive impairment; Cognitive functioning; Cognitive remediation; Subsyndromic depressive symptoms

Abstract

Recently, Functional Remediation (FR) has proven to be effective in improving the functional outcome of euthymic bipolar patients. The aim of this study was to test the efficacy of the FR program in a subsample of euthymic bipolar II patients (BPII). A post-hoc analyses were undertaken using data of 53 BPII outpatients who had participated in a multicenter, rater-blind, randomized, controlled trial exploring the efficacy of FR (n=17) as compared with a Psychoeducation group (PSY) (n=19) and a treatment as usual control group (TAU n=17). The primary outcome variable was the functional improvement defined as the mean change in the Functioning Assessment Short Test (FAST) from baseline to endpoint after the intervention. Regarding the treatment effect, data reveal a significant functional improvement from baseline to endpoint, suggestive for an interaction between program pertinence and time (pre-post). Nevertheless, Tukey's post-hoc test only revealed a trend in favor of a better outcome for FR when compared to the other two groups. We also found an interaction between program pertinence and time when analysing the subdepressive symptoms, with BPII patients in FR showing a significant reduction when compared to the PSY group. Our results suggest that the FR appears to be effective in improving the overall functional outcome in BPII, as well as in reducing subdepressive symptoms.

© 2014 Elsevier B.V. and ECNP. All rights reserved.

1. Introduction

Bipolar disorder type II (BPII) has been often considered as a mild form of bipolar disorder type I (BPI). However, nowadays it is known that BPII is not a less impairing variant of bipolar disorder. The disease burden in BPII does not differ from that observed in BPI regarding clinical severity, impairment, patterns of comorbidity, suicide attempts, family history and treatment patterns (Merikangas et al., 2007). Moreover, a recent report has demonstrated that BPII patients are as functionally impaired as BPI (Rosa et al., 2010). Similarly, evidence from recent reviews focused on neurocognition suggests that both subtypes of bipolar disorders present with similar neurocognitive deficits, with BPII only showing subtle differences when compared to BPI (Sole et al., 2011; Bora et al., 2011). Furthermore, there exists also a link between neurocognitive deficits and daily functioning in bipolar disorder, similarly to that found in schizophrenia (Depp et al., 2012; Tabares-Seisdedos et al., 2008; losifescu, 2012). In fact, a study with a sample of BPII patients reported that impairment in executive functions as well as the presence of subthreshold depressive symptoms were the best predictors of psychosocial outcome (Sole et al., 2012).

Taking all these data into account, it seems necessary to implement therapies focused on enhancing functional outcome in bipolar disorder. In addition to cognitive remediation programs (Deckersbach et al., 2010), recently some psychological interventions, including mindfulness, have been used in order to improve cognition and functioning in bipolar disorder (Stange et al., 2011;Lahera et al., 2013). However, there is still a need for further innovative treatment approaches (Fuentes-Dura et al., 2012;Anaya et al., 2012), especially concerning to BPII population. In this sense, Martinez-Aran and colleagues proposed a new therapeutic intervention named Functional Remediation (FR), designed exclusively for bipolar patients, aimed at improving neurocognition in order to achieve a functional recovery

(Martinez-Aran et al., 2011). The efficacy of this new intervention has been recently tested in a randomized controlled trial (RCT), suggesting that the FR program is a promising tool to ameliorate daily functioning in bipolar patients (Torrent et al., 2013). Nevertheless, RCTs devoted to analyze the impact of psychological therapies on BPII patients are scarce (Colom et al., 2009a). In fact, most available therapies targeting BP, derive from studies carried out with BPI or mixed samples of BPI and BPII patients. Therefore, it cannot be concluded whether therapies for BPII patients require adjustments to meet the specific needs showed by this group of patients or not.

Hence, the present subanalysis was aimed to assess the efficacy of the Functional Remediation program specifically in a sample of bipolar II patients concerning global psychosocial functioning, assessed by changes in the means of the Functioning Assessment Short Test (FAST). We hypothesized that bipolar II patients in the Functional Remediation group would experience greater improvement in global psychosocial functioning compared with the other two intervention groups (Psychoeducation and TAU).

2. Experimental procedures

This was a post-hoc, exploratory subanalysis of data obtained from a larger study focused on the efficacy of FR in the psychosocial functioning improvement in euthymic bipolar patients (Torrent et al., 2013). BPI and BPII patients were hereby randomized by means of a computer-generated sequence to either a structured group of FR, a manual-based group psychoeducative intervention (PSY), or to join a group of patients only following pharmacological treatment as usual (TAU). It was designed as a multicenter, randomized, rater-blind outpatient trial conducted between 2009 and 2011, which was registered with the number NCT 01370668 in www.clinicaltrial.gov. Detailed explanations of the FR intervention and study procedures can be gathered from the original article (Torrent et al., 2013) and the FR manual (in press). The patients were mainly recruited from different specialised bipolar care centers in Spain (Vieta, 2013, 2011).

Download English Version:

https://daneshyari.com/en/article/320143

Download Persian Version:

https://daneshyari.com/article/320143

<u>Daneshyari.com</u>